AAPL307.92+13.54 (+4.60%) ▲|ABBV258.75+7.69 (+3.06%) ▲|ABT95.06+2.88 (+3.12%) ▲|ACN137.59+6.46 (+4.93%) ▲|ADBE221.29+10.31 (+4.89%) ▲|AMAT582.22-68.69 (-10.55%) ▼|AMD508.29-32.59 (-6.03%) ▼|AMGN370.97+9.64 (+2.67%) ▲|AMT167.10+1.02 (+0.61%) ▲|AMZN244.18+2.48 (+1.02%) ▲|AVGO358.48-10.86 (-2.94%) ▼|AXP349.14+2.09 (+0.60%) ▲|BA223.36+4.78 (+2.19%) ▲|BAC58.41+0.05 (+0.08%) ▲|BKNG182.11-0.53 (-0.29%) ▼|BLK990.65+10.27 (+1.05%) ▲|BMY57.13+1.32 (+2.36%) ▲|BNY145.30-0.72 (-0.49%) ▼|BRK-B505.86+6.12 (+1.22%) ▲|C138.41-1.72 (-1.23%) ▼|CAT952.74-38.67 (-3.90%) ▼|CL94.85+2.09 (+2.25%) ▲|CMCSA23.33-0.41 (-1.71%) ▼|COF203.34-1.48 (-0.72%) ▼|COP103.65+0.43 (+0.41%) ▲|COST948.52+23.85 (+2.58%) ▲|CRM165.63+2.40 (+1.47%) ▲|CSCO112.42-4.60 (-3.93%) ▼|CVS103.51-1.30 (-1.24%) ▼|CVX168.28+2.59 (+1.56%) ▲|DE616.89-10.75 (-1.71%) ▼|DHR196.52+2.80 (+1.45%) ▲|DIS98.04+2.33 (+2.43%) ▲|DUK128.25+2.48 (+1.97%) ▲|EMR137.50-2.02 (-1.45%) ▼|FDX311.28-2.61 (-0.83%) ▼|GD369.77+8.50 (+2.35%) ▲|GE374.86-0.08 (-0.02%) ▼|GEV1,096.07-38.29 (-3.38%) ▼|GILD129.82+3.85 (+3.05%) ▲|GM74.40-1.12 (-1.49%) ▼|GOOG353.34-4.55 (-1.27%) ▼|GOOGL356.52-4.70 (-1.30%) ▼|GS1,011.89-7.73 (-0.76%) ▼|HD354.31+3.47 (+0.99%) ▲|HON226.01+4.26 (+1.92%) ▲|IBM285.80-0.45 (-0.16%) ▼|INTC119.47-7.55 (-5.94%) ▼|INTU275.16+8.08 (+3.03%) ▲|ISRG421.27+18.89 (+4.69%) ▲|JNJ261.48+7.50 (+2.95%) ▲|JPM332.72-1.35 (-0.40%) ▼|KO83.07+1.78 (+2.18%) ▲|LIN545.31+11.76 (+2.20%) ▲|LLY1,207.93+16.19 (+1.36%) ▲|LMT537.11+15.29 (+2.93%) ▲|LOW224.59+2.67 (+1.20%) ▲|LRCX346.53-44.73 (-11.43%) ▼|MA536.68+14.24 (+2.73%) ▲|MCD278.21+8.78 (+3.26%) ▲|MDLZ60.43+1.08 (+1.82%) ▲|MDT82.49+3.29 (+4.15%) ▲|META584.66-28.25 (-4.61%) ▼|MMM159.84-0.13 (-0.08%) ▼|MO72.28+0.74 (+1.03%) ▲|MRK128.13+2.76 (+2.20%) ▲|MS212.02+0.16 (+0.08%) ▲|MSFT390.75+6.47 (+1.68%) ▲|MU962.11-70.17 (-6.80%) ▼|NEE87.29+0.92 (+1.06%) ▲|NFLX78.19+4.00 (+5.39%) ▲|NKE43.95+0.89 (+2.07%) ▲|NOW106.02+0.22 (+0.21%) ▲|NVDA193.10-4.48 (-2.27%) ▼|ORCL139.27-3.23 (-2.27%) ▼|PEP143.74+2.58 (+1.83%) ▲|PFE24.28+0.40 (+1.65%) ▲|PG151.04+3.61 (+2.45%) ▲|PLTR131.35+5.62 (+4.47%) ▲|PM180.47+2.78 (+1.56%) ▲|QCOM173.30-8.62 (-4.74%) ▼|RTX196.72+4.94 (+2.58%) ▲|SBUX104.01+0.62 (+0.60%) ▲|SCHW96.54+0.76 (+0.79%) ▲|SO97.26+2.14 (+2.25%) ▲|SPG224.69+1.69 (+0.76%) ▲|T20.12-0.37 (-1.78%) ▼|TMO520.06+6.73 (+1.31%) ▲|TMUS174.81+1.75 (+1.01%) ▲|TSLA392.09-33.22 (-7.81%) ▼|TXN289.85-8.57 (-2.87%) ▼|UBER73.36+0.70 (+0.96%) ▲|UNH422.34-4.20 (-0.98%) ▼|UNP280.32+2.59 (+0.93%) ▲|UPS109.48-0.07 (-0.06%) ▼|USB61.30-0.66 (-1.07%) ▼|V359.66+8.58 (+2.44%) ▲|VZ41.48-0.52 (-1.23%) ▼|WFC85.18-0.76 (-0.88%) ▼|WMT111.84+3.02 (+2.77%) ▲|XOM136.93+0.65 (+0.48%) ▲|AAPL307.92+13.54 (+4.60%) ▲|ABBV258.75+7.69 (+3.06%) ▲|ABT95.06+2.88 (+3.12%) ▲|ACN137.59+6.46 (+4.93%) ▲|ADBE221.29+10.31 (+4.89%) ▲|AMAT582.22-68.69 (-10.55%) ▼|AMD508.29-32.59 (-6.03%) ▼|AMGN370.97+9.64 (+2.67%) ▲|AMT167.10+1.02 (+0.61%) ▲|AMZN244.18+2.48 (+1.02%) ▲|AVGO358.48-10.86 (-2.94%) ▼|AXP349.14+2.09 (+0.60%) ▲|BA223.36+4.78 (+2.19%) ▲|BAC58.41+0.05 (+0.08%) ▲|BKNG182.11-0.53 (-0.29%) ▼|BLK990.65+10.27 (+1.05%) ▲|BMY57.13+1.32 (+2.36%) ▲|BNY145.30-0.72 (-0.49%) ▼|BRK-B505.86+6.12 (+1.22%) ▲|C138.41-1.72 (-1.23%) ▼|CAT952.74-38.67 (-3.90%) ▼|CL94.85+2.09 (+2.25%) ▲|CMCSA23.33-0.41 (-1.71%) ▼|COF203.34-1.48 (-0.72%) ▼|COP103.65+0.43 (+0.41%) ▲|COST948.52+23.85 (+2.58%) ▲|CRM165.63+2.40 (+1.47%) ▲|CSCO112.42-4.60 (-3.93%) ▼|CVS103.51-1.30 (-1.24%) ▼|CVX168.28+2.59 (+1.56%) ▲|DE616.89-10.75 (-1.71%) ▼|DHR196.52+2.80 (+1.45%) ▲|DIS98.04+2.33 (+2.43%) ▲|DUK128.25+2.48 (+1.97%) ▲|EMR137.50-2.02 (-1.45%) ▼|FDX311.28-2.61 (-0.83%) ▼|GD369.77+8.50 (+2.35%) ▲|GE374.86-0.08 (-0.02%) ▼|GEV1,096.07-38.29 (-3.38%) ▼|GILD129.82+3.85 (+3.05%) ▲|GM74.40-1.12 (-1.49%) ▼|GOOG353.34-4.55 (-1.27%) ▼|GOOGL356.52-4.70 (-1.30%) ▼|GS1,011.89-7.73 (-0.76%) ▼|HD354.31+3.47 (+0.99%) ▲|HON226.01+4.26 (+1.92%) ▲|IBM285.80-0.45 (-0.16%) ▼|INTC119.47-7.55 (-5.94%) ▼|INTU275.16+8.08 (+3.03%) ▲|ISRG421.27+18.89 (+4.69%) ▲|JNJ261.48+7.50 (+2.95%) ▲|JPM332.72-1.35 (-0.40%) ▼|KO83.07+1.78 (+2.18%) ▲|LIN545.31+11.76 (+2.20%) ▲|LLY1,207.93+16.19 (+1.36%) ▲|LMT537.11+15.29 (+2.93%) ▲|LOW224.59+2.67 (+1.20%) ▲|LRCX346.53-44.73 (-11.43%) ▼|MA536.68+14.24 (+2.73%) ▲|MCD278.21+8.78 (+3.26%) ▲|MDLZ60.43+1.08 (+1.82%) ▲|MDT82.49+3.29 (+4.15%) ▲|META584.66-28.25 (-4.61%) ▼|MMM159.84-0.13 (-0.08%) ▼|MO72.28+0.74 (+1.03%) ▲|MRK128.13+2.76 (+2.20%) ▲|MS212.02+0.16 (+0.08%) ▲|MSFT390.75+6.47 (+1.68%) ▲|MU962.11-70.17 (-6.80%) ▼|NEE87.29+0.92 (+1.06%) ▲|NFLX78.19+4.00 (+5.39%) ▲|NKE43.95+0.89 (+2.07%) ▲|NOW106.02+0.22 (+0.21%) ▲|NVDA193.10-4.48 (-2.27%) ▼|ORCL139.27-3.23 (-2.27%) ▼|PEP143.74+2.58 (+1.83%) ▲|PFE24.28+0.40 (+1.65%) ▲|PG151.04+3.61 (+2.45%) ▲|PLTR131.35+5.62 (+4.47%) ▲|PM180.47+2.78 (+1.56%) ▲|QCOM173.30-8.62 (-4.74%) ▼|RTX196.72+4.94 (+2.58%) ▲|SBUX104.01+0.62 (+0.60%) ▲|SCHW96.54+0.76 (+0.79%) ▲|SO97.26+2.14 (+2.25%) ▲|SPG224.69+1.69 (+0.76%) ▲|T20.12-0.37 (-1.78%) ▼|TMO520.06+6.73 (+1.31%) ▲|TMUS174.81+1.75 (+1.01%) ▲|TSLA392.09-33.22 (-7.81%) ▼|TXN289.85-8.57 (-2.87%) ▼|UBER73.36+0.70 (+0.96%) ▲|UNH422.34-4.20 (-0.98%) ▼|UNP280.32+2.59 (+0.93%) ▲|UPS109.48-0.07 (-0.06%) ▼|USB61.30-0.66 (-1.07%) ▼|V359.66+8.58 (+2.44%) ▲|VZ41.48-0.52 (-1.23%) ▼|WFC85.18-0.76 (-0.88%) ▼|WMT111.84+3.02 (+2.77%) ▲|XOM136.93+0.65 (+0.48%) ▲|
37.8 C
New York
Thursday, July 2, 2026

Tag: email

CAR FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR) between February 16, 2024 and February 10, 2025, both dates inclusive (the “Class Period”), of the important June 24, 2025 lead plaintiff deadline.

Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence – Hagens Berman

NSSC Investors with Losses Encouraged to Contact Hagens Berman Before June 24th Deadline in Securities Class Action
NSSC Investors with Losses Encouraged to Contact Hagens Berman Before June 24th Deadline in Securities Class Action

Backblaze Investor News: If You Have Suffered Losses in Backblaze, Inc. (NASDAQ: BLZE), You Are Encouraged to Contact The Rosen Law Firm About Your...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Backblaze, Inc. (NASDAQ: BLZE) resulting from allegations that Backblaze may have issued materially misleading business information to the investing public.

D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth

Glasgow, June 15, 2025 (GLOBE NEWSWIRE) --

In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle-building benefits of anabolic steroids, but with a natural and safer approach.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025.

Nuclear Air Filtration for HVAC Managers: Why the Nuclear Comeback Demands Next-Gen Filtration Standards

The Big Reveal: What HVAC Managers Must Know About High-Performance Filtration. Camfil Nuclear air filters are used for containment control during dismantling or maintenance work at a nuclear sites.
The Big Reveal:  What HVAC Managers Must Know About High-Performance Filtration. Camfil Nuclear air filters are used for containment control during dismantling or maintenance work at a nuclear sites.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Bitfarms Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BITF

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bitfarms Ltd. (NASDAQ: BITF) between March 21, 2023 and December 9, 2024, both dates inclusive (the “Class Period”), of the important July 8, 2025 lead plaintiff deadline.

GA (Int’l) Capital Management Limited Issues Statement Regarding SFC Restriction Notice

HONG KONG, June 14, 2025 (GLOBE NEWSWIRE) -- GA (Int’l) Capital Management Limited confirms that the Securities and Futures Commission (SFC) of Hong Kong issued a temporary restriction notice on June 6 2025, pursuant to Sections 204 and 205 of the Securities and Futures Ordinance (SFO). This action follows an incident involving a mainland China-registered corporate client who submitted fraudulent tax documentation during compliance onboarding.

Abacus Global Management, Inc. (ABL) Shares Tumble Following Second Morpheus Report – Hagens Berman

SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Investors in Abacus Global Management, Inc. (NASDAQ: ABL) experienced another substantial decline in share price today following the release of a second scathing report from Morpheus Research. Morpheus, a collective of financial analysts known for their focus on uncovering alleged fraud and corporate malfeasance, has now published two critical analyses of Abacus within a week, alleging the life settlements company has engaged in improper accounting.

TEMPUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. and Encourages Investors to...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or the “Company”)  (NASDAQ: TEM) in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired Tempus securities between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

ROCKET ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Rocket Pharmaceuticals, Inc. and Encourages Investors to...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ:RCKT) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Rocket securities between February 27, 2025 to May 26, 2025, both dates inclusive (the “Class Period”). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

TEM Investor Notice: Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Tempus AI, Inc. Class Action

Robbins LLP is Investigating Allegations that Tempus AI, Inc. (TEM) Misled Investors Regarding its Business Prospects

RCKT Investor Notice: Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Rocket Pharmaceuticals, Inc.

Robbins LLP is Investigating Allegations that Rocket Pharmaceuticals, Inc. (RCKT) Misled Investors Regarding the Viability and Efficacy of RP-A501

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEmail